Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Fineline Cube Jan 27, 2026
Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026
Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Fineline Cube Jan 27, 2026
Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Fineline Cube Jan 27, 2026
Company Drug

Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy

Fineline Cube Jan 27, 2026
Company Deals

WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services

Fineline Cube Jan 3, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment

Fineline Cube Jan 3, 2024

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...

Company Drug

BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments

Fineline Cube Jan 3, 2024

The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...

Company Deals

Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization

Fineline Cube Jan 3, 2024

Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...

Company Deals

Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare

Fineline Cube Jan 3, 2024

Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...

Company Deals

Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership

Fineline Cube Jan 3, 2024

Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...

Company Deals

Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management

Fineline Cube Jan 3, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...

Company Legal / IP

Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France

Fineline Cube Jan 2, 2024

French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...

Company Legal / IP

J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products

Fineline Cube Jan 2, 2024

A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...

Policy / Regulatory

China’s CDE Releases Guidelines for CGT Clinical Trials Communication

Fineline Cube Jan 2, 2024

The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...

Policy / Regulatory

China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...

Policy / Regulatory

China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...

Company Deals

Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology

Fineline Cube Jan 2, 2024

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...

Company Drug

Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment

Fineline Cube Jan 2, 2024

US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...

Company Deals

Roche Secures Diagnostics Deal with LumiraDx for $295M

Fineline Cube Jan 2, 2024

Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...

Company Deals

Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug

Fineline Cube Jan 2, 2024

vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...

Company Drug

Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study

Fineline Cube Jan 2, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment

Fineline Cube Jan 2, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...

Company Drug

Hainan Poly Pharm’s Novel Nanomedicine PLAT001 Gets US FDA Approval for Clinical Trials

Fineline Cube Jan 2, 2024

Hainan Poly Pharm Co., Ltd (SHE: 300630), a Chinese pharmaceutical company, has announced that it...

Company Deals

CareRay Digital Medical Technology to Acquire 30% Stake in UK’s ISDI for USD 15.2 Million

Fineline Cube Jan 2, 2024

CareRay Digital Medical Technology Co., Ltd, a company based in Suzhou (SHA: 688607), has announced...

Posts pagination

1 … 370 371 372 … 614

Recent updates

  • BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s
  • Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy
  • ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO
  • Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease
  • Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BioArctic Partner Eisai Submits EMA Application for Four-Week Lecanemab Dosing in Alzheimer’s

Company Drug

Nuance Pharma Secures NMPA Review for Ensifentrine COPD Maintenance Therapy

Company

ASCP Launches $250K Grants for mCRC Biomarker Testing with Pfizer, ASCO

Company Deals

Boehringer Ingelheim Licenses Simcere’s SIM0709 Bispecific for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.